While chemotherapy has helped to improve survival for cancer patients, the side effects lead to substantial detrimental effects on quality of life tht can be debilitating;these side effects, including cognitive impairments, have become a major focus of research. Chemotherapy-related cognitive impairment (CRCI) is characterized by difficulty in memory, attention, concentration and executive function. CRCI is most pronounced and severe during chemotherapy (in up to 80% of patients), however, it can last for years following treatment in up to 35% of survivors. With over 13 million cancer survivors in the US, it is estimated that up to 4 million survivors could be living with long-lasting effects of CRCI. CRCI is particularly significant because long-term cognitive impairment can develop, CRCI negatively impacts quality of life, and CRCI can affect treatment adherence. I'm currently conducting a NCI K Award in patient-oriented research investigating interventions targeting inflammation to alleviate cognitive difficulties in breast cancer patients receiving chemotherapy;my laboratory focuses solely on CRCI research. One of the main hypotheses in our field is that inflammation may drive cognitive impairment in these patients. While this is becoming well-accepted in our field, there is a gap in understanding the nature of this inflammatory response as most clinical research studies have limited access to biological correlates of CRCI. There is also a lack of investigators that can carefully assess neuro-immune factors in basic science models as well as in people. I am proposing to use my knowledge in basic immunology, neuroimmunology, and neuroscience with my behavioral research training in cognitive science, neuropsychology and clinical cancer control to address these gaps in the field. While this research focuses on CRCI, it has broad implications for many areas of cancer control and survivorship. Part I of this application involves careful assessment and understanding of the role of inflammation on brain function and neuroinflammation in chemotherapy animal models (using a breast cancer chemotherapy paradigm;Part IA) and following up with analyzing possible etiological factors in a breast cancer patient cohort that is being treated with the same chemotherapy regimen (Part IB). In Part II of this application, we will utilize animal models to develop and test intervention for cancer-related cognitive impairment (this is not commonly done in cancer control research) which will allow us to move forward with the most successful interventions for testing in clinical research. Overall, this proposal will allow us to better understand immunologic and neurotoxic effects of CRCI, develop interventions for CRCI, and improve the overall public health burden of this troublesome side effect.

Public Health Relevance

Up to 75% of cancer patients experience chemotherapy-related cognitive impairment (CRCI;often termed chemobrain) during their chemotherapy treatments. CRCI includes difficulties in memory, attention, concentration and executive function. CRCI effects can last for many years after treatment and have a negative impact on many facets of quality of life. There are no effective treatments for CRCI and the exact etiology is unknown. This project will provide information on CRCI etiology and intervention development and assessment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
NIH Director’s New Innovator Awards (DP2)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MOSS-C (56))
Program Officer
O'Mara, Ann M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Rochester
Schools of Dentistry
United States
Zip Code
Williams, AnnaLynn M; Shah, Raven; Shayne, Michelle et al. (2018) Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J Neuroimmunol 314:17-23
Janelsins, Michelle C; Heckler, Charles E; Peppone, Luke J et al. (2017) Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol 35:506-514
Magnuson, Allison; Mohile, Supriya; Janelsins, Michelle (2016) Cognition and Cognitive Impairment in Older Adults with Cancer. Curr Geriatr Rep 5:213-219
Janelsins, Michelle C; Heckler, Charles E; Thompson, Bryan D et al. (2016) A clinically relevant dose of cyclophosphamide chemotherapy impairs memory performance on the delayed spatial alternation task that is sustained over time as mice age. Neurotoxicology 56:287-293
Williams, A M; Janelsins, M C; van Wijngaarden, E (2016) Cognitive function in cancer survivors: analysis of the 1999-2002 National Health and Nutrition Examination Survey. Support Care Cancer 24:2155-2162
Williams, Annalynn M; Zent, Clive S; Janelsins, Michelle C (2016) What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br J Haematol 174:835-46
Janelsins, Michelle C; Peppone, Luke J; Heckler, Charles E et al. (2016) YOCAS©® Yoga Reduces Self-reported Memory Difficulty in Cancer Survivors in a Nationwide Randomized Clinical Trial: Investigating Relationships Between Memory and Sleep. Integr Cancer Ther 15:263-71
Kerns, Sarah L; Kundu, Suman; Oh, Jung Hun et al. (2015) The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention. Semin Radiat Oncol 25:281-91